Skip to main content

Advertisement

Springer Nature Link
Log in

Idiopathic Inflammatory Myopathies

Optimum Immunosuppressive Treatment

  • Disease Management
  • Published:
BioDrugs Aims and scope Submit manuscript

Summary

The idiopathic inflammatory myopathies include polymyositis and dermato-myositis, which tend to be responsive to drug therapy, and inclusion body myositis, which is often unresponsive or only partially responsive to drugs.

Corticosteroids are considered the first line treatment of these disorders, and as well as being anti-inflammatory are immunosuppressive when used at dosages above prednisolone 20 mg/day or equivalent. In those patients who are refractory to corticosteroids, or are prone to develop complications from corticosteroids, second line drugs such as methotrexate, azathioprine or intravenous immunoglobulin should be introduced. These therapies tend to be slow acting, but response often occurs in 4 to 6 weeks and allows the dosage of corticosteroid to be reduced more rapidly.

In those occasional patients with inflammatory myopathies that are refractory to corticosteroids and second line agents, one should consider adding in a third line agent such as cyclosporin, chlorambucil or cyclophosphamide. Although most clinicians would use these immunosuppressive drugs singly in combination with corticosteroids, multiple drug therapy should be considered in severe refractory cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mastaglia FL, Laing NG. Investigations of muscle disease. J Neurol Neurosurg Psychiatry 1996; 60: 256–74

    Article  PubMed  CAS  Google Scholar 

  2. Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisolone, azathioprine and methotrexate and a comparison of their efficacy. Am J Med 1993; 94: 379–87

    Article  PubMed  CAS  Google Scholar 

  3. Benbassat J, Gefel D, Larhott K, et al. Prognostic factors in polymyositis/dermatomyositis: a computer assisted analysis of ninety two cases. Arthritis Rheum 1985; 28: 249–55

    Article  PubMed  CAS  Google Scholar 

  4. Fauci AS, Dale DL. The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest 1974; 53: 240–6

    Article  PubMed  CAS  Google Scholar 

  5. Zanker B, Walz G, Wieder KJ, et al. Evidence that glucocor-ticosteroids block expression of the human interleukin-6 gene by accessory cells. Transplantation 1990; 49: 183–5

    Article  PubMed  CAS  Google Scholar 

  6. Von Knebel Doeberitz M, Koch S, Droznel H, et al. Glucocorticoid hormones reduce the expression of major histocompatibility class I antigens on human epithelial cells. Eur J Immunol 1990; 20: 35–41

    Article  Google Scholar 

  7. Oddis CV. Therapy for myositis. Curr Opin Rheumatol 1991; 3: 919–24

    Article  PubMed  CAS  Google Scholar 

  8. Henriksson KG, Sandstedt P. Polymyositis treatment and prognosis: a study of 107 patients. Acta Neurol Scand 1982; 65: 280–300

    Article  PubMed  CAS  Google Scholar 

  9. Rosenberg NL, Ringel SP. Adult polymyositis and dermatomyositis. In: Mastaglia FL, editor. Inflammatory diseases of muscle. Oxford: Blackwell Scientific Publications, 1988: 87–106

    Google Scholar 

  10. Engel WK, Borenstein A, DeVivo DC, et al. High single dose alternate-day prednisolone in treatment of dermatomyositis/ polymyositis complex. Trans Am Neurol Assoc 1972; 97: 272–5

    Google Scholar 

  11. Segal R, Yarom M, Tartakovsky B. Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum 1990; 20: 190–9

    Article  PubMed  CAS  Google Scholar 

  12. Metzger AL, Bohan A, Goldberg LS, et al. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 1974; 81: 182–9

    PubMed  CAS  Google Scholar 

  13. Arnett FC, Whelton JC, Zizic TM, et al. Methotrexate therapy in polymyositis. Ann Rheum Dis 1973; 32: 536–46

    Article  PubMed  CAS  Google Scholar 

  14. Miller LC, Sisson BA, Tucker LB, et al. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 1992; 35: 1143–9

    Article  PubMed  CAS  Google Scholar 

  15. Bunch TW. Prednisolone and azathioprine for polymyositis: long-term follow-up. Arthritis Rheum 1981; 24: 45–8

    Article  PubMed  CAS  Google Scholar 

  16. Ramirez G, Asherson RA, Khamashta MA, et al. Adult-onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment. Semin Arthritis Rheum 1990; 20: 114–20

    Article  PubMed  CAS  Google Scholar 

  17. Dalakas MC. Current treatment of the inflammatory myopathies. Curr Opin Rheum 1994; 6: 595–601

    Article  CAS  Google Scholar 

  18. Confavreux C, Saddier P, Grimaud J, et al. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 1996; 46: 1607–12

    Article  PubMed  CAS  Google Scholar 

  19. Heskmatt J, Saunders C, Peters AM, et al. Cyclosporin in juvenile dermatomyositis. Lancet 1989; I: 1063–6

    Article  Google Scholar 

  20. Leuck CJ, Trend PT, Swash M. Cyclosporin in the management of polymyositis and dermatomyositis. J Neurol Neurosurg Psychiatry 1991; 54: 1007–8

    Article  Google Scholar 

  21. Grau JM, Herrero C, Casademont J, et al. Cyclosporin A as first choice for dermatomyositis. J Rheumatol 1994; 21: 381–2

    PubMed  CAS  Google Scholar 

  22. Al-Janadi M, Smith CD, Karsh J. Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis. J Rheumatol 1989; 16: 1592–6

    PubMed  CAS  Google Scholar 

  23. Cronin ME, Miller FW, Hicks JE, et al. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 1989; 16: 1225–8

    PubMed  CAS  Google Scholar 

  24. Bombardieri S, Hughes GRV, Neri R, et al. Cyclophosphamide in severe polymyositis. Lancet 1989; I: 1138–9

    Article  Google Scholar 

  25. Sinoway PA, Callen JP. Chlorambucil: an effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum 1993; 36: 319–24

    Article  PubMed  CAS  Google Scholar 

  26. Kahn MF, Arlet J, Bloch-Michel H, et al. Acute leukemias after treatment using cytotoxic agents for rheumatological purpose. Nouv Presse Med 1979; 8: 1393–7

    PubMed  CAS  Google Scholar 

  27. Lang BA, Laxen RM, Murphy G, et al. Treatment of dermatomyositis with intravenous immunoglobulin. Am J Med 1991; 91: 169–72

    Article  PubMed  CAS  Google Scholar 

  28. Sussman GL, Pruzanski W. Treatment of inflammatory myopathy with intravenous gammaglobulin. Curr Opin Rheum 1995; 7: 510–5

    Article  CAS  Google Scholar 

  29. Cherin P, Piette JC, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991; 91: 162–8

    Article  PubMed  CAS  Google Scholar 

  30. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993–2000

    Article  PubMed  CAS  Google Scholar 

  31. Dalakas MC. Clinical benefits and immunopathological correlates of intravenous immunoglobulin in the treatment of inflammatory myopathies. Clin Exp Immunol 1996; 104Suppl. 1: 55–60

    PubMed  Google Scholar 

  32. Cherin P, Piette JC, Wechsler B, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol 1994; 21: 1092–7

    PubMed  CAS  Google Scholar 

  33. Bertorini TE, Nance AM, Horner LH, et al. Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerve 1996; 19: 388–91

    Article  PubMed  CAS  Google Scholar 

  34. Dau PC. Plasmapheresis in idiopathic inflammatory myopathy. Arch Neurol 1981; 38: 544–52

    Article  PubMed  CAS  Google Scholar 

  35. Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992; 326: 1380–4

    Article  PubMed  CAS  Google Scholar 

  36. Engle WK, Lighter AS, Galdi AP. Polymyositis: remarkable response to total body irradiation. Lancet 1981; I: 658

    Google Scholar 

  37. Morgan SH, Bernstein RM, Coppen J, et al. Total body irradiation and the course of polymyositis. Arthritis Rheum 1985; 28: 831–5

    Article  PubMed  CAS  Google Scholar 

  38. Leff RL, Miller FW, Hicks J, et al. The treatment of inclusion body myositis: a retrospective review and a randomised, prospective trial of immunosuppressive therapy. Medicine 1993; 72: 225–35

    Article  PubMed  CAS  Google Scholar 

  39. Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol 1992; 19: 1385–9

    PubMed  CAS  Google Scholar 

  40. Soueidan SA, Dalakas MC. Treatment of inclusion body myositis with high-dose intravenous immunoglobulin. Neurology 1993; 43: 876–9

    Article  PubMed  CAS  Google Scholar 

  41. Amato AA, Barohn RJ, Jackson CE, et al. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994; 444: 1516–8

    Article  Google Scholar 

  42. Zilko PJ, Mastaglia FL, Laing B. Intravenous immunoglobulin (IVIg) in steroid resistant inflammatory myopathies. Aust NZ J Med 1993; 23: 543

    Google Scholar 

  43. Wallace DJ, Metzger AL, White KK. Combination immunosuppressive treatment of steroid-resistant dermatomyositis/polymyositis. Arthritis Rheum 1985; 28: 590–2

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Australian Neuromuscular Research Institute, Queen Elizabeth II Medical Centre, Perth, Western Australia, 6009, Australia

    Paul J. Zilko, Frank L. Mastaglia & Beverley A. Phillips

Authors
  1. Paul J. Zilko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank L. Mastaglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Beverley A. Phillips
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zilko, P.J., Mastaglia, F.L. & Phillips, B.A. Idiopathic Inflammatory Myopathies. BioDrugs 7, 262–272 (1997). https://doi.org/10.2165/00063030-199707040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199707040-00003

Keywords

Search

Navigation